Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Respiratory Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1428567

CKD-497 inhibits NF-kB signaling and ameliorates inflammation CKD-497 inhibits NF-kB signaling and ameliorates inflammation and pulmonary fibrosis in ovalbumin-induced asthma and and pulmonary fibrosis in ovalbumin-induced asthma and particulate matter-induced airway inflammatory diseases particulate matter-induced airway inflammatory diseases

Provisionally accepted
Hyejeong Kim Hyejeong Kim *Jihye Choi Jihye Choi Jaeok Seo Jaeok Seo Hyungjoon Lim Hyungjoon Lim Sung K. Kang Sung K. Kang
  • Chong Kun Dang pharmaceutical Corp, Yongin-si, Republic of Korea

The final, formatted version of the article will be published soon.

    Air pollution, allergens, and bacterial infections cause pathological respiratory disorders worldwide. CKD-497, derived from the rhizome of Atractylodes japonica and the fruits of Schisandra chinensis, can relieve cough and facilitate phlegm expectoration. However, its protective action against allergic asthma and fine dust-induced lung inflammation and its underlying mechanisms have not been investigated. Herein, we established mouse models of ovalbumin-induced asthma and particulate matter (PM)-induced pulmonary inflammation.Oral administration of CKD-497 effectively attenuated airway inflammation and mucus production and decreased the production of the proinflammatory cytokines IL-1β, IL-6, and TNF-α. CKD-497 alleviated leukocyte infiltration, including neutrophils, and fibrillary collagen deposition in PM 10 -treated mice. Pretreatment of the macrophage cell line, RAW264.7, with CKD-497 prevented lipopolysaccharide-induced inflammation via NF-kB signaling pathway. Thus, CKD-497 may be a functional supplement that can protect against respiratory diseases by inhibiting pulmonary and airway inflammation induced by allergens and air pollution.

    Keywords: Ovalbumin, Asthma, fine dust, airway inflammation, Functional Food, respiratory disease

    Received: 06 May 2024; Accepted: 26 Jul 2024.

    Copyright: © 2024 Kim, Choi, Seo, Lim and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hyejeong Kim, Chong Kun Dang pharmaceutical Corp, Yongin-si, Republic of Korea

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.